Feyza Bora

Dr. Feyza Bora


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 June 2021 in TURKISH JOURNAL OF MEDICAL SCIENCES
Verified
Journal Article
Open access
SOSavas Ozturk
Savas Ozturk
KTKenan Turgutalp
Kenan Turgutalp
MAMustafa Arici
Mustafa Arici
HÇHakkı ÇETİNKAYA
Hakkı ÇETİNKAYA
MAMehmet Riza Altiparmak
Mehmet Riza Altiparmak
KAKenan Ateş
Kenan Ateş
AAbstract Background/aim: Hospital-acquired acute kidney injury (HA-AKI) may commonly develop in Covid-19 patients and is expected to have higher mortality. There is little comparative data looking for the effect of HA-AKI on mortality of chronic kidney disease (CKD) patients and a control group of general population suffering from Covid-19. HA-AKI development was assessed in a group of stage 3-5 CKD patients and control group without CKD among adult patients hospitalized for Covid-19. The role of AKI development on the outcome (in-hospital mortality and admission to the intensive care unit [ICU]) of patients with and without CKD was compared. Among 621 hospitalized patients (age 60 [IQR:47-73]), women: 44.1%), AKI developed in 32.5% of the patients, as stage 1 in 84.2%, stage 2 in 8.4% and, stage 3 in 7.4%. AKI developed in 48.0 % of CKD patients, whereas in 17.6% of patients without CKD. CKD patients with HA-AKI had the highest mortality rate of 41.1 % compared to 14.3 % of patients with HA-AKI but no CKD (p<0.001). However, patients with AKI+non-CKD had similar rates of ICU admission, mechanical ventilation, and death rate as patients with CKD without AKI. Adjusted mortality risk of the AKI+non-CKD group (HR: 9.0, 95%CI:1.9-44.2) and AKI+CKD group (HR: 7.9, 95%CI:1.9-33.3) were significantly higher than non-AKI+non-CKD group. AKI frequently develops in hospitalized patients due to Covid-19 and is associated with high mortality. HA-AKI has worse outcome whether it develops in patients with or without CKD, but the worst outcome was seen in AKI+CKD patients.

22 April 2024 in Therapeutic Apheresis and Dialysis
Verified
Journal Article
Closed access
TSTuncay Sahutoglu
Tuncay Sahutoglu
RDRamazan Daniş
Ramazan Daniş
IPIrem Pembegul
Irem Pembegul
IOIlyas Ozturk
Ilyas Ozturk
CHCan Hüzmeli
Can Hüzmeli
RKRümeyza Kazancıoğlu
Rümeyza Kazancıoğlu

1 November 2016
Verified
Journal Article
Open access
FBFeyza Bora
Feyza Bora
FYFatih Yılmaz
Fatih Yılmaz
TBTaner Bora
Taner Bora
Ecstasy (MDMA; 3,4-methylenedioxymethylamphetamine) is an illicit drug that has been increasingly abused by young people. Its effects include euphoria, enhanced sociability and heightened mental awareness. These come about via the increase of serotonin in both the central nervous system and the sympathetic nervous system. Despite the drug's prevalent abuse, serious or adverse effects are rare. Due to personal pharmacokinetics, effects from the same dosage vary according to the individual. Fatal instances may include acute hyponatremia, hyperthermia (>42 °C), disseminated intravascular coagulation (DIC) resulting from hyperthermia affecting the kidneys, and non-traumatic rhabdomyolysis. However, it is seldom the case that hyponatremia and hyperthermia co-exist. Hyponatremia is thought to be caused by HMMA - a metabolite of MDMA. Hyponatremia is caused by the inappropriate secretion of arginine vasopressin (AVP) and the excessive intake of hypotonic liquid accompanied by increased hyperthermia. Symptomatic, even deadly hyponatremia is seen more frequently in females, with the effects of oestrogen on arginine vasopressin believed to be the cause. Onset in such cases is acute, and treatment should be given to symptomatic patients as quickly as possible, with 3% saline administered when necessary. Reasons for acute kidney injury may include rhabdomyolysis, malign hypertension, and necrotizing vasculitis.

22 December 2020 in Seminars in Dialysis
Verified
Journal Article
Closed access
PDF file
FYFatih Yılmaz
Fatih Yılmaz
FBFeyza Bora
Feyza Bora
RÇRamazan Çetinkaya
Ramazan Çetinkaya
MGMustafa Tekinalp Gelen
Mustafa Tekinalp Gelen
GSGültekin Süleymanlar
Gültekin Süleymanlar
FEFevzi Ersoy
Fevzi Ersoy

13 May 2020 in International Urology and Nephrology
Verified
Journal Article
Closed access
PDF file
HSHasan Sozel
Hasan Sozel
SKSadi Koksoy
Sadi Koksoy
SOSebahat Ozdem
Sebahat Ozdem
FYFatih Yılmaz
Fatih Yılmaz
FBFeyza Bora
Feyza Bora
FEF. Fevzi Ersoy
F. Fevzi Ersoy

24 August 2022 in Therapeutic Apheresis and Dialysis
Verified
Journal Article
Closed access
FBFeyza Bora
Feyza Bora
BABengisu Aslan
Bengisu Aslan
FSFunda Sarı
Funda Sarı
FYFatih Yılmaz
Fatih Yılmaz
FEFettah Fevzi Ersoy
Fettah Fevzi Ersoy
MUMemnune Sena Ulu
Memnune Sena Ulu